Renal Health in the Kimberley region

Dr Emma Griffiths

- Renal GP, KRS
- Medical Coordinator, RCSWA
- Public Health Registrar and PhD Candidate, UWA



HISTORY OF THE SERVICE

- October 2002: Kimberley Satellite Dialysis Centre (KSDC) established in partnership with Royal Perth Hospital - first Australian dialysis unit to be managed by an Aboriginal Community Controlled Health Service
- April 2004: KSDC at full capacity
- August 2012: Opening of current 4 chair Fitzroy Renal Health Centre (FRHC)
- April 2013: Opening of current 11 chair Derby Renal Health Centre (DRHC)
- May 2013: Opening of 6 chair Kununurra Renal Health Centre (KRHC)
- October 2014: KRS becomes a company in it's own right
- May 2017: KSDC (Now Broome Renal Health Centre BRHC), DRHC, FRHC and KRHC at full capacity







RATES OF CKD IN INDIGENOUS AUSTRALIANS

- NT community data vs AusDiab:
 - Relative risk for Indigenous Australians •
 - Up to 5 times for proteinuria •
- 2011 2013 ABS Australian Health Survey:
 - Relative risk for Indigenous Australians: ٠
 - Up to 4 times for CKD* ٠
 - Relative risk for remote living Indigenous Australian ٠

Up to 20 times for ESKD ٠



WA Non-Indigenous 176,900 10.1% Indigenous 10,200 22.8%	
ligenous Australians:	
ralians:	
rvey:	
а	
ralians	NT Non-Indigenous 9,800 7.9% Indigenous 12,000 32,4%

Non-Indigenous 106,0 Indigenous 3,300 17.59 Prevalence of CKD (eGFR < 6- mL/min/1.73 m²) Kimberley vs. Australian Health Survey 2011 - 2012



Prevalence of albuminuria Kimberley vs. Australia Health Survey 2011- 2012



RATES OF ESKD IN INDIGENOUS AUSTRALIANS

ANZDATA reporting system:

- 251 Indigenous Australians commenced RRT in 2014
- Diabetes was the most commonly identified primary disease (32%) followed by glomerulonephritis (22%)
 - Few biopsies done
- RRT incidence in remote areas the highest in the world



Reference = ANZDATA Registry. 38th Report, Chapter 12: Indigenous People and End Stage Kidney Disease. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia. 2016. Available at: http://www.anzdata.org.au

ANZDATA: INCIDENCE OF ESKD



Note: Only New South Wales, Queensland, Western Australia, South Australia and the Northern Territory are included. Source: Linked ANZDATA Registry, AIHW National Mortality Database and National Death Index.

Figure 6.2: Total incidence of ESKD, by age and Indigenous status, 2003-2007



COMMUNITY CASE STUDY

Community "A" in the Western Desert:

Population = 915, people with results = 389
Prevalence of Kidney disease:

- By age 25: 52% chance of signs of CKD
- By age 45: 62% chance of signs of CKD

If you are aged between 45 and 55:

- There is a 12% chance you have a reduced eGFR
- There is a 22% chance you have an ACR > 100
- There is a high chance someone in your family has had ESKD





Reference = routinely collected data analysed for KRS reporting requirements, as of 30th June 2016



SATELLITE HAEMODIALYSIS

INDIGENOUS HEALTH

Haemodialysis outcomes of Aboriginal and Torres Strait Islander patients of remote Kimberley region origin

Julia V Marley, Hannah K Dent, Maree Wearne, Cherelle Fitzclarence, Carmel Nelson, Karen Siu, Kevin Warr and David Atkinson

s has been widely reported elsewhere, over the past 20 years, there has been an epidemic of end-stage kidney disease (ESKD) among Aboriginal and Torres Strait Islander people in remote areas of Australia.¹⁻⁵ Known risk factors include intrauterine growth retardation, various illnesses in childhood, the early onset and poor control of hypertension and diabetes, and possibly smoking.⁶

There have been limited reports on the outcomes of Aboriginal and Torres Strait Islander people on dialysis in Australia, and those that have been published have generally documented poor patient survival when compared with non-Indigenous patients in Australia.4,5,7 From 1993 to 1996, the median survival for patients undergoing peritoneal dialysis (PD) and haemodialysis (HD) was 3.3 and 6.5 years for Aboriginal and Torres Strait Islander people, respectively.5 When all forms of renal replacement therapy (RRT) were included, patient survival for Aboriginal and Torres Strait Islander people was less than a third that of non-Indigenous natients During 1994 and 1995 almost

ABSTRACT

Objectives: To compare the clinical outcomes and mortality rates of Aboriginal and Torres Strait Islander people of Kimberley origin receiving haemodialysis (HD) treatment with other subsets of Aboriginal and Torres Strait Islander HD patients (Northern Territory, Western Australia excluding the Kimberley region, the rest of Australia) and Australian non-Indigenous HD patients.

Design, participants and setting: Retrospective identification of Aboriginal and Torres Strait Islander patients of Kimberley origin and analysis of secondary data from the Australia and New Zealand Dialysis and Transplant Registry; this group was compared with other Australian patients receiving HD treatment from 1 January 2003 to 31 December 2007.

Main outcome measures: Clinical outcome measures; comorbid conditions; death rates per 100 patient-years, unadjusted and adjusted (for age, sex, comorbid conditions, late referral to nephrologist treatment).

Results: Seventy per cent of HD treatments for Aboriginal and Torres Strait Islander patients of Kimberley origin was provided in the Kimberley. They had comparable adjusted mortality rates to non-Indigenous Australian patients (adjusted mortality rate ratio, 0.80; 95% CI, 0.51–1.23).

Conclusions: This is the first report showing similar mortality rates for Aboriginal and Torres Strait Islander people exclusively from a remote area of Australia and non-Indigenous Australians receiving HD treatment. HD treatment delivered closer to home can be safe and effective in remote areas.

MJA 2010; 193: 516-520



SATELLITE HAEMODIALYSIS

- All Kimberley Renal Health Centres currently operating at full capacity
- As of May 2017:
 - Seven patients now waiting in Perth (as of May 2017)
 - Twenty-five patients on RRT pathway in the region with an $eGFR \le 15$
- Services limited to Broome, Kununurra, Derby, Fitzroy Crossing





HOME THERAPIES

- Can bring patients closer to home
- No specific ceiling on patient numbers
- WACHS Renal Dialysis Plan 2010 to 2021:
 - Target of 35% of RRT to be via home therapies



HOWEVER...



Home Therapies

Peritoneal Dialysis in the Kimberley:

- Higher rates of technique failure
- Higher rates peritonitis
- Significantly shorter:
 - Time to first episode peritonitis
 - Overall survival time on PD

Need for:



Original Research

Peritoneal dialysis outcomes of Indigenous Australian patients of remote Kimberley origin

Julia V. Marley, PhD,^{1,2} Sarah Moore, FRACGP,^{1,2} Cherelle Fitzclarence, FRACGP,² Kevin Warr, FRACP,³ and David Atkinson, MBBS^{1,2}

¹The Rural Clinical School of Western Australia, The University of Western Australia, and ²Kimberley Aboriginal Medical Services Council, Broome, and ³Department of Renal Medicine, Royal Perth Hospital, Perth, Western Australia, Australia

- Enhanced local support for home therapies
- Consideration of patient pathways to home therapies care, including low acuity satellite facilities
- Beware the "bad reputation" following treatment failures
 - Good engagement between stakeholders



TRANSPLANT

Table 8.3. Ethnicity of Recipients Transplanted 2010-2014

Country	Ethnicity	2011	2012	2013	2014	2015
	Total	825 (100.0%)	845 (100.0%)	883 (100.0%)	913 (100.0%)	949 (100.0%)
	Caucasian	657 (79.6%)	674 (79.8%)	682 (77.2%)	696 (76.2%)	686 (72.3%)
	Aboriginal/TSI	28 (3.4%)	20 (2.4%)	31 (3.5%)	41 (4.5%)	36 (3.8%)

- Fewer transplants
- More infective complications
- Families unable to donate to families
- No new transplants for Kimberley Aboriginal patients in the last three years



DATA: AKI PROJECT





ACUTE KIDNEY INJURY

0-44 45-54 55-64 65+ Total 0-44 45-54 55-64 65+ Total

AKI episodes per 100 000

Most common conditions associated with AKI (ICD-10):

Kimberley (n = 324)		National (n = 113 768)		
Number of episodes with diagnosis	% episodes with diagnosis	Number of episodes with diagnosis	% episodes with diagnosis	
Infection (n = 155) [Pneumonia (n = 42), Skin (n = 38), UTI (n = 20)]	48%	Circulatory / vascular (n = 21852)	19%	
Circulatory / vascular (n = 50) [Heart failure (n = 24)]	15%	Respiratory (n = 14088)	12%	
Endocrine / metabolic [Diabetes and related (n = 26)]	14%	Infection (n = 10474)	9%	

CULTURALLY RESPONSIVE HEALTH PROMOTION RESOURCES – EVALUATION NEEDED



which permit to be interpreted which in the second state of the second state.

Kidney Check



It's never too late to make positive changes to your lifestyle!



Eating well and keeping active can improve long term health and help to maintain good kidney function

CASE DEFINITION

Chronic Kidney Disease (CKD) is either of the following, persisting for at least three months, repeated on at least two occasions:

- Markers of kidney damage (e.g. proteinuria, haematuria or structural abnormalities on renal imaging) and / or:
- GFR < 60 mL/min/1.73m².

Both eGFR and ACR are required to determine the stage and risk category of CKD as albuminuria is one of the biggest known risk factors for progression to End Stage Kidney Disease (ESKD).

TABLE 1: KDIGO STAGING OF CKD

	ACR (mg/mmol)			
eGFR	Normal	Micro-	Macro-	
	<3.0	albuminuria	albuminuria	
		3.0-30	>30	
Stage 1	NO CKD	MODERATE	HIGH RISK	
eGFR ≥90	(unless other markers of	RISK CKD	СКД	
Stage 2	kidney damage			
eGFR 60-89	detected)			
Stage 3	MODERATE	HIGH RISK	VERY HIGH	
eGFR 45-59	RISK CKD	CKD	RISK CKD	
Stage 3b	HIGH RISK	VERY HIGH		
eGFR 30-44	СКД	RISK CKD		
Stage 4	VERY HIGH			
eGFR 15-29	RISK CKD			
Stage 5				
eGFR <15				
or dialysis				

SCREENING

Up to 60% of adults in some Kimberley communities have markers of Chronic Kidney Disease (CKD).

Increased creatinine occurs late in CKD and implies significant kidney damage.

Screen annually for patients with any of the following risk factors:

- Aboriginal or Torres Strait Islander person aged >= 15 years of age;
- Smoking;
- Obesity (BMI > 30kg/m²);
- Family history of CKD;
- History of cardiovascular disease (e.g. stroke/CVA, heart attack/MI, peripheral vascular disease / PVD);
- Hypertension;
- Diabetes;
- Previous acute kidney injury (AKI);
- Use of nephrotoxic drugs (e.g. NSAIDS).

Patients assessed as not having risk factors should be regularly screened for the development of risk factors over time.

Screening for CKD requires:

- Blood pressure (BP) measurement;
- Blood test for urea, electrolytes and creatinine (UEC);
- Urine test for albumin:creatinine ratio (ACR):
 - Dipstick prior to sending and document result;
 - If leucocytes, blood and/or nitrates consider possible UTI / STI (see Table 2).

TABLE 2: OTHER CAUSES OF ABNORMAL KIDNEY

SCREENING TESTS AND APPROPRIATE FOLLOW-UP

Abnormality	Management
Proteinuria with	Send urine for MCS and consider
abnormal urine dipstick	UTI treatment in discussion with
due to suspected urinary	GP. Follow appropriate STI
tract infection (UTI) or	guidelines for counselling, testing
urethritis from sexually	and treating possible STI (See
transmissible infection	RESOURCES). Repeat ACR with
(STI).	proof of cure of infection in three
	months or as clinically indicated.
Proteinuria / raised	Repeat screening when patient
creatinine after vigorous	has not exercised in the previous
exercise or heavy protein	24 hours or fasting sample.
consumption.	
Isolated proteinuria in	Recheck ACR on morning first
person without other risk	void urine collected immediately
factors for CKD aged less	on first standing
than 30 years (i.e.	
possible orthostatic	
proteinuria).	
Increase in creatinine	Creatinine rise to ≤25%
after commencement of	acceptable – see management
ACE-inhibitor / ARB.	section. Monitor weekly until
	stable

Considerations in interpreting screening results:

- Creatinine levels vary with muscle mass: eGFR on laboratory reports may under or overestimate renal function in people with extremes of body size, muscular diseases or amputations – calculators can be used to factors in body weight (see RESOURCES);
- Abnormalities persisting less than 3 months indicate acute kidney injury (AKI) which increases the risk of subsequent CKD;
- Episodes of AKI should be investigated for a cause and documented in the medical record;
- Newly abnormal eGFR should be repeated within a week to identify rapidly declining renal function.



Colour Coding Scale - Last Date

This provides the numbers of patients categorised by their latest ACR and eGFR observations in the date range.

Last eGFR Category	A1	A2	A3	No Result
G1	620	320	152	967
G2	196	128	83	323
G3a	23	22	52	63
G3b	9	12	33	54
G4	1	7	33	36
G5		1	14	41
No Result	116	66	28	

Last ACR Category

RESEARCH PRIORITIES

http://www.cari.org.au/docs/Research%20Priorities%20in%20Chronic%20Kidney%20Disease 7Feb2 014.pdf

How effective are lifestyle programs (diet, exercise and smoking cessation) for preventing deterioration in kidney function in patients with early CKD?

What are the best interventions to improve the decision-making process of people faced with HD?

Does active implementation of clinical practice guidelines in general practice improve kidney health in patients with early CKD?

Does provision of culturally appropriate information about early CKD modify acknowledgement, medication adherence, and health service uptake in patients with early CKD?



Thank you for your time and attention



